Cubist Systematic Strategies LLC Sells 16,275 Shares of Bristol-Myers Squibb Co (BMY)

Share on StockTwits

Cubist Systematic Strategies LLC cut its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 34.9% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 30,377 shares of the biopharmaceutical company’s stock after selling 16,275 shares during the period. Cubist Systematic Strategies LLC’s holdings in Bristol-Myers Squibb were worth $1,681,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BMY. W.G. Shaheen & Associates DBA Whitney & Co bought a new position in shares of Bristol-Myers Squibb during the first quarter valued at approximately $101,000. Institutional & Family Asset Management LLC bought a new position in shares of Bristol-Myers Squibb during the first quarter valued at approximately $106,000. Centerpoint Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 373.1% during the first quarter. Centerpoint Advisors LLC now owns 1,774 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 1,399 shares in the last quarter. CSat Investment Advisory L.P. bought a new position in shares of Bristol-Myers Squibb during the second quarter valued at approximately $113,000. Finally, Landaas & Co. WI ADV bought a new position in shares of Bristol-Myers Squibb during the second quarter valued at approximately $131,000. Hedge funds and other institutional investors own 72.29% of the company’s stock.

Shares of BMY opened at $60.69 on Friday. Bristol-Myers Squibb Co has a twelve month low of $49.96 and a twelve month high of $70.05. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.40 and a quick ratio of 1.28. The company has a market capitalization of $98.61 billion, a price-to-earnings ratio of 17.85, a PEG ratio of 1.52 and a beta of 1.02.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The business had revenue of $5.70 billion during the quarter, compared to the consensus estimate of $5.48 billion. During the same period in the previous year, the firm posted $0.74 earnings per share. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. equities analysts predict that Bristol-Myers Squibb Co will post 3.62 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, November 1st. Stockholders of record on Friday, October 5th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, October 4th. This represents a $1.60 annualized dividend and a dividend yield of 2.64%. Bristol-Myers Squibb’s payout ratio is currently 53.16%.

Several equities research analysts have weighed in on the stock. SunTrust Banks restated a “buy” rating and issued a $67.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, July 31st. UBS Group downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and set a $57.00 target price for the company. in a research note on Monday, May 21st. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, July 14th. BMO Capital Markets raised their target price on shares of Bristol-Myers Squibb from $47.00 to $51.00 and gave the company a “market perform” rating in a research note on Monday, July 23rd. Finally, Credit Suisse Group raised their target price on shares of Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $62.89.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Article: How Do I Invest in Dividend Stocks

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.